In Utero Amniotic Fluid Stem Cell Therapy Protects Against Myelomeningocele via Spinal Cord Coverage and Hepatocyte Growth Factor Secretion

Despite the poor prognosis associated with myelomeningocele (MMC), the options for prenatal treatments are still limited. Recently, fetal cellular therapy has become a new option for treating birth defects, although the therapeutic effects and mechanisms associated with such treatments remain unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Yushi, Ochiai, Daigo, Masuda, Hirotaka, Sato, Yu, Otani, Toshimitsu, Fukutake, Marie, Ikenoue, Satoru, Miyakoshi, Kei, Okano, Hideyuki, Tanaka, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Fetal and Neonatal Stem Cells
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811697/
https://www.ncbi.nlm.nih.gov/pubmed/31407874
http://dx.doi.org/10.1002/sctm.19-0002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811697/
https://www.ncbi.nlm.nih.gov/pubmed/31407874
http://dx.doi.org/10.1002/sctm.19-0002

Ejemplares similares